The American pharmaceutical company Moderna announced this Thursday that it has started clinical trials with a booster vaccine against COVID-19 that combines its original formula with a specific one in response to the omicron variant.
In a statement, the company said it plans to involve some 375 people who had already received two doses of the vaccine and a booster dose in this second phase of the study, which is being carried out in the United States.
These tests are in addition to those that Moderna is doing only with a specific booster dose to combat omicron, which it announced last January.
“Our goal has been to stay ahead of the virus and we are committed to continuing to generate and share data with public health authorities as they prepare for the fall booster season.”, pointed out in the note the CEO, Stephane Bancel.
Bancel He pointed out that the messenger RNA technology on which the vaccine is based allows changes to be made quickly as variants of the virus emerge.
Like modernPfizer and BioNTech they are also conducting trials with a possible booster dose designed to be more effective against omicron.
Source: Gestion
Ricardo is a renowned author and journalist, known for his exceptional writing on top-news stories. He currently works as a writer at the 247 News Agency, where he is known for his ability to deliver breaking news and insightful analysis on the most pressing issues of the day.
